ARDX | Ticker Profile - Titan Protect

ARDX

Ardelyx, Inc.

Healthcare · Biotechnology · NGM

$5.56

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.5B

Total market value of the company

Trailing P/E

N/A

Forward P/E

11.98

Based on estimated future earnings — lower means cheaper

Rev Growth

+27.5%

Year-over-year revenue change

Profit Margin

-13.6%

How much profit the company keeps from each dollar of revenue

ROE

-39.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$16.00

+188% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 9 analysts covering this stock

About Ardelyx, Inc.

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

https://www.ardelyx.com

Country: United States Employees: 489 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.321

Positive but modest risk-adjusted returns

Kelly Fraction

0.0018

Marginal edge — very small allocation suggested

Calmar Ratio

-0.049

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-2.8%

Historical annualised return based on price data

Max Drawdown

-56.7%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.61

Less volatile than the market — more defensive

52W High

$8.40

34% below the year high

52W Low

$3.49

59% above the year low

Avg Volume

3,552,611

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

9.9%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.24

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

157.53

Heavy leverage — higher financial risk if revenues decline

Current Ratio

3.49

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.93

Like current ratio but excludes inventory — stricter test

Gross Margin

74.6%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-34.7%

Profit from core operations before interest and tax

Free Cash Flow

$86,375

Positive — the business generates more cash than it spends

Revenue (TTM)

$428M

Total revenue over the last 12 months

Net Income

$-58,060,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$19.00

Target Median

$16.00

Target Low

$13.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go